TABLE 1.

Characteristics of patients with episodes of ventricular tachycardia

Number of patients	n = 43
Male sex	36 (84%)
Ischemic cardiomyopathy	20 (47%)
Non‐ischemic cardiomyopathy (DCM/sarcoidosis/HCM/amyloidosis/Brugada S/unclassified)	23 (53%) (10/3/2/1/1/6)
NYHA class (I/II/III/IV)	(12/19/11/1)
ß‐blocker use	31 (72%)
ACE‐I or ARB use	28 (65%)
Cardiotonic agent use	7 (16%)
Antiarrhythmic drug use	13 (30%)
EF (%)	36 ± 15
CRT‐D	16 (37%)

Data are presented as numbers, unless otherwise indicated.

Abbreviated: ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; Brugada S, Brugada syndrome; CRT‐D, cardiac resynchronization therapy defibrillator; DCM, dilated cardiomyopathy; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; NYHA, New York Heart Association